Sarepta Therapeutics (NASDAQ: SRPT) stock is experiencing a remarkable pre-market surge of 12.48% on Thursday, following the release of its exceptional second-quarter financial results. The biopharmaceutical company, specializing in gene therapy and RNA-targeted approaches for rare diseases, has significantly outperformed analyst expectations, driving investor enthusiasm.

The company reported adjusted earnings per share (EPS) of $2.02 for Q2, dramatically surpassing the analyst consensus estimate of $0.67 by 201.49%. This represents a staggering 369.77% increase from the $0.43 per share reported in the same period last year. Sarepta's quarterly sales also impressed, coming in at $611.091 million, beating the analyst consensus estimate of $528.390 million by 15.65%. This figure marks a substantial 68.38% year-over-year increase from $362.931 million.

Adding to the positive sentiment, Sarepta announced that its Q2 2025 net product revenues totaled $513.1 million. The company also stated it is on track to realize over $100 million in cost savings through the end of 2025, demonstrating effective cost management alongside strong growth. These impressive results, showcasing both top-line growth and bottom-line improvement, have clearly fueled investor confidence and are driving the stock's significant pre-market rally.